ADHD Drug CTx-1301 Receives Complete Response Letter - Top_Thought_Leaders - MDSpire

ADHD Drug CTx-1301 Receives Complete Response Letter

Company says the agency requested additional Chemistry, Manufacturing and Controls information.

  • By

  • Kathryn Wighton

  • June 2, 2026

  • 2 min

Share

Top Thought Leaders in Pathology

Brief introduction explaining scope and methodology.

Original Source(s)

ADHD Drug CTx-1301 Receives Complete Response Letter

  • by Kathryn Wighton

  • June 2, 2026

Related Content

Burnout among medical doctors working in paediatric intensive care units in Bulgaria

Dual-Site aiTBS for Suicidal Ideation in Adolescents With Major Depressive Disorder: A Randomized Clinical

Toward Participatory Precision Health With Co-Designed Recommendations: Systematic Review of Just-in-Time Adaptive Interventions in Adolescents and Young Adults